Drugs Made In America Acquisition II Corp. Unit
Drugs Made In America Acquisition II Corp. Unit
Your view on DMIIU
Overview
What the company does, where it operates, and who runs it.
About Drugs Made In America Acquisition II Corp. Unit
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Roger Bendelac
- Headquarters
- 420 Lexington Avenue, New York, NY, US
- Industry
- Shell Companies
- Sector
- Financial Services
- CEO
- Roger Bendelac
- Headquarters
- 420 Lexington Avenue, New York, NY, US
DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business.
The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing.
Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Drugs Made In America Acquisition II Corp. Unit from FRC's valuation model, read against the market price. DMIIU last traded at $10.25, 33.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Drugs Made In America Acquisition II Corp. Unit. Starting points for Drugs Made In America Acquisition II Corp. Unit: P/E 33.8, EPS $0.26, beta 0.06 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Drugs Made In America Acquisition II Corp. Unit. Drugs Made In America Acquisition II Corp. Unit does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Drugs Made In America Acquisition II Corp. Unit. Trailing twelve-month EPS for Drugs Made In America Acquisition II Corp. Unit stands at $0.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Drugs Made In America Acquisition II Corp. Unit. Drugs Made In America Acquisition II Corp. Unit has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
More Shell Companies companies
Market cap
- GIXXUGigCapital9 Corp. UnitsNASDAQ$261M
- GLBBGlobal Quest Ltd.OTC$1,005
- GLEDGalaxyEdge Acquisition CorporationNYSE$163M
- GLRIGlori Energy Inc.OTC$6,474
- GMZPGEMZ CorporationOTC$222,599
- GPACGeneral Purpose Acquisition Corp.NASDAQ$240M
- GPACUGeneral Purpose Acquisition Corp.NASDAQ$241M
- GPATGP-Act III Acquisition Corp.NASDAQ$176M
- GPATUGP-Act III Acquisition Corp.NASDAQ$392M
- GPATWGP-Act III Acquisition Corp.NASDAQ$275M
- GPLBGreen Planet Bioengineering Co LtdOTC$342,109
- GRGGGreen For Energy, Inc.OTC
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Drugs Made In America Acquisition II Corp. Unit executives and directors. Shares of Drugs Made In America Acquisition II Corp. Unit have traded between $9.94 and $10.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Drugs Made In America Acquisition II Corp. Unit. Coverage tracks Drugs Made In America Acquisition II Corp. Unit within Shell Companies (Financial Services). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Drugs Made In America Acquisition II Corp. Unit.